Literature DB >> 33691646

Prolonged apnea after ECT in organophosphorus poisoning - the need to redefine norms.

Shibu Sasidharan1, Harpreet Singh Dhillon2.   

Abstract

BACKGROUND: Poisoning and deaths by organo-phosphorous (OP) compounds are one of the major causes of death in developing and poor countries, and a common admission in the emergency ward and the ICU. OP compounds act by irreversibly binding to pseudocholinesterase enzyme and hence prolong the apnea in patients being given suxamethonium. We present a unusual case of OP poisoning (OPP) in which prolonged apnea ensued in a patient of severe depression following MECT (modified electroconvulsive therapy) in which suxamethonium was used as muscle relaxant, in whom we were cautious of the side-effect of prior organophosphorus poisoning. Since the cases of OPP are very high worldwide, a thorough knowledge of the interaction of the action of the drug and the receptors on which it acts takes pride of place. This article highlights the nuances in the field of psychiatry and anaesthesia in diagnosis and management of prolonged apnea after ECT. CASE
PRESENTATION: A 53/F patient consumed OP 38 days prior to MECT. Since existing literature recommend a delay of 4 weeks and a subminimal dose of suxamethonium to prevent prolonged apnea, both these points were taken into consideration. Despite 38 days post exposure to OP, and a dose of succinylcholine of < 0.3 mg/kg, the patient remained apneic for 3 h. Suxamethionum apnea was managed with elective ventilation. After recovery, patient had no residual effect. Subsequently her pseudocholinesterase levels were done which were found to be very low.
CONCLUSION: This case is being presented to emphasize that behaviour of post synaptic receptors cannot be relied upon after OP poisoning and pseudocholinesterase levels needs to be mandatorily checked, irrespective of duration post-exposure. In strong suspects dibucaine number and fluoride number also needs to be estimated.

Entities:  

Keywords:  Depression; Electroconvulsive therapy; MECT; Organophosphorus poisoning; Prolonged apnea; Pseudocholinesterase; Succinylcholine

Year:  2021        PMID: 33691646      PMCID: PMC7948321          DOI: 10.1186/s12888-021-03150-0

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  11 in total

1.  An alternate method for estimating the dose-response relationships of neuromuscular blocking drugs.

Authors:  A F Kopman; M M Klewicka; G G Neuman
Journal:  Anesth Analg       Date:  2000-05       Impact factor: 5.108

Review 2.  THE CHOLINESTERASES AND THEIR SIGNIFICANCE TO THE ANAESTHETIST USING MUSCLE RELAXANTS.

Authors:  M D VICKERS
Journal:  Br J Anaesth       Date:  1963-09       Impact factor: 9.166

3.  Qualitative defects of pseudocholinesterase activity.

Authors:  J G Mone; W E Mathie
Journal:  Anaesthesia       Date:  1967-01       Impact factor: 6.955

4.  Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India.

Authors:  Indumathi Manoharan; Stacy Wieseler; Paul G Layer; Oksana Lockridge; Rathnam Boopathy
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

Review 5.  Cholinesterase. Its significance in anaesthetic practice.

Authors:  L Davis; J J Britten; M Morgan
Journal:  Anaesthesia       Date:  1997-03       Impact factor: 6.955

6.  Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.

Authors:  Avinash Waghmare; Channaveerachari Naveen Kumar; Jagadisha Thirthalli
Journal:  Gen Hosp Psychiatry       Date:  2009-12-02       Impact factor: 3.238

7.  Prolonged apnea following succinylcholine administration in undiagnosed acute organophosphate poisoning.

Authors:  E B Sener; E Ustun; S Kocamanoglu; A Tur
Journal:  Acta Anaesthesiol Scand       Date:  2002-09       Impact factor: 2.105

8.  Prolonged apnea following modified electroconvulsive therapy with suxamethonium.

Authors:  T M Omprakash; P Surender
Journal:  Indian J Psychol Med       Date:  2011-07

9.  Butyrylcholinesterase as a prognostic marker: a review of the literature.

Authors:  Lidia Santarpia; Ilenia Grandone; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-06       Impact factor: 12.910

10.  Butyrylcholinesterase deficiency identified by preoperative patient interview.

Authors:  Serin Lee; Jung Woo Han; Eun Sung Kim
Journal:  Korean J Anesthesiol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.